Lymph node dissection identifies patients at high risk of kidney cancer spread

A recent study published in the journal Science Direct suggests that lymph node dissection (lymphadenectomy) in patients with non-metastatic renal cell carcinoma (RCC) at high risk of recurrence/spread could be used to identify patients who are most likely to benefit from adjuvant therapy. In the study, the researchers retrospectively assessed the progression of the disease in […]

read more

Potential urine biomarkers for small renal masses

A recent study, published in the International Journal of Urology, has identified two potential biomarkers for the presence of malignant small renal masses in the urine. The study investigated aquaporin 1 and perilipin 2 to determine if these biomarkers were predictive of malignancy. During the study with 57 patients, the presence of aquaporin 1 and […]

read more

ASCO GU 2019: Questions and lessons moving forward from CARMENA: A medical oncologist’s perspective

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from medical oncologist Dr Lauren Harshman, Dana-Farber Cancer Institute, Boston, USA, suggests that this is an […]

read more

New cancer drug payment system could speed up access to treatments

Cancer Research UK and the Greater Manchester Health and Social Care Partnership has produced a report suggesting a new system for reimbursement of cancer drugs by the NHS. The report suggests that paying for cancer drugs based on how well they work in practice could help patients get new treatments faster. This new flexible system, […]

read more

Sources of frustration for patients with kidney cancer

This observation study involved 450 patients with renal cell carcinoma (RCC) and was conducted via social media and patient networking platforms. The survey was designed to investigate frustration points associated with the care of RCC patients. Overall, 71.5% reported frustration, including emotional (48.4%) and practical (23.1%). The most common points of frustration included fear of […]

read more

ASCO GU 2019: Interviews with the experts

The following interviews with kidney cancer experts were recorded by Practice Update and UroTodayat the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Pembrolizumab and axitinib as first-line therapy Key data from ASCO GU 2019 on mRCC Frontline RCC treatment from ASCO GU 2019: Practice implications Pembrolizumab for non-clear cell RCC […]

read more

ASCO GU 2019: Nivolumab-ipilimumab survival benefit in advanced kidney cancer

New 30-month survival data from the CheckMate 214 study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Additional 30-month follow-up data from the phase 3 CheckMate 214 trial confirms the survival benefit of the nivolumab plus ipilimumab combination over sunitinib as a first-line treatment for patients […]

read more

ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib […]

read more

ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Toni Choueiri from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA, presented updated results from the JAVELIN Renal 101 clinical trial. The results showed that treatment with a […]

read more

ASCO GU 2019: Nivolumab monotherapy for non-clear cell renal cell carcinoma

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Nicholas Vogelzang of the Comprehensive Cancer Centers of Nevada, Las Vegas, and colleagues presented updated safety data and efficacy of nivolumab in patients with non-clear cell renal cell carcinoma (RCC) in […]

read more
Showing 11 to 20 of 479 results
  TOP